Image not available

Alsaikhan B et al, 2011: Shock wave lithotripsy in patients requiring anticoagulation or antiplatelet agents

Alsaikhan B, Andonian S
Department of Urology, McGill University Health Centre, Montreal, QC


Abstract

Extracorporeal shockwave lithotripsy (SWL) remains the only truly minimally invasive procedure for the treatment of upper tract nephrolithiasis. Recently, there has been a recent rise in the patients on antiplatelet agents. Therefore, the aim of the present study is to review the literature available regarding SWL in these high-risk patients requiring anti-coagulation therapy. Alternative therapies to SWL are also presented.

Can Urol Assoc J. 2011 Feb;5(1):53-7. doi: 10.5489/cuaj.09140
PMID: 21470517 [PubMed - in process] PMCID: PMC3036760

Rate this blog entry:
0
 

Comments 1

Hans-Göran Tiselius on Friday, 22 July 2011 14:21

This is a useful review of considerations to be made before ESWL and other surgical procedures in patients on anticoagulation therapy. Patients were stratified in low, intermediate and high CVD-risk groups. For the low-risk patients anti-platelet agents can be withheld for a maximum of 7 days. Substitution with unfractionated heparin was not recommended. For intermediate- and high-risk patients individualized treatment following consultation with a cardiologist is advised. For the latter groups of patients, whenever possible surgery should be postponed 6-12 month after the CVD episode. It is of particular importance to note if the patients has drug-eluting stents.

Since ESWL directed towards the renal tissue is associated with a potential risk of bleeding and that the use of anticoagulants have become so common, it is indeed important to pay attention both to the risk of not recognizing this medical treatment and to the risk of interrupting it.

Hans-Göran Tiselius

This is a useful review of considerations to be made before ESWL and other surgical procedures in patients on anticoagulation therapy. Patients were stratified in low, intermediate and high CVD-risk groups. For the low-risk patients anti-platelet agents can be withheld for a maximum of 7 days. Substitution with unfractionated heparin was not recommended. For intermediate- and high-risk patients individualized treatment following consultation with a cardiologist is advised. For the latter groups of patients, whenever possible surgery should be postponed 6-12 month after the CVD episode. It is of particular importance to note if the patients has drug-eluting stents. Since ESWL directed towards the renal tissue is associated with a potential risk of bleeding and that the use of anticoagulants have become so common, it is indeed important to pay attention both to the risk of not recognizing this medical treatment and to the risk of interrupting it. Hans-Göran Tiselius
Guest
Sunday, 28 May 2017
STORZ MEDICAL AG
Lohstampfestrasse 8
8274 Tägerwilen
Switzerland
Tel.: +41 (0)71 677 45 45
Fax: +41 (0)71 677 45 05

www.storzmedical.com
Personal data
Address
Contact data
Message